IP Library Granted Patent US 7,405,049
Granted Patent B2
US 7,405,049 · App. 10/511,758 · Granted Jul 29, 2008

Method for diagnosing inflammatory diseases and infections by the determination of LASP-1 immunoreactivity

Assignee: B.R.A.H.M.S. Aktiengesellschaft
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,405,049
App. No.
10/511,758
Granted
Jul 29, 2008
Kind
B2
Abstract

Method for early diagnosis and diagnosis, for prognosis and assessment of the severity and for therapy-accompanying monitoring of inflammatory diseases and infections, in particular sepsis-like systemic infections and Alzheimer's disease, in which the presence and/or amount of the protein LASP-1 (SEQ ID NO:1) or of the protein LAP-1 (SEQ ID NO:16) or of an immunoreactive fragment of one of these proteins in free and/or protein-bound form is determined, preferably as immunoreactivity, in a biological fluid, or optionally a tissue sample, of a patient, and conclusions are drawn with respect to the presence, the expected course, the severity or the success of a therapy of the inflammatory disease or of the infection from the presence and/or amount of the proteins determined.

Claims (12)

1. A method for confirming a clinical diagnosis of a sepsis in a patient suspected of having sepsis, the method comprising:

a) determining the concentration of LIM and SH3 Domain Protein-1 (LASP-1) and at least one further biomarker for sepsis in a blood or serum sample from said patient; and

b) comparing said concentrations to the corresponding concentration in a control sample,

wherein an elevated concentration of a LASP-1 protein and at least one further biomarker for sepsis with reference to said control sample is indicative of sepsis.

2. The method of claim 1 , wherein the concentration of LASP-1 protein is determined by an immunodiagnostic assay of the sandwich type.

3. The method of claim 2 , wherein the immunoreactivity of the LASP-1 protein from amino acid positions 121-187 of SEQ ID NO: 1 is determined.

4. The method of claim 2 , wherein the immunodiagnostic assay employs antibody reagents produced from a protein having SEQ ID NO:13 or from a protein having SEQ ID NO: 17.

5. The method of claim 3 , wherein the LASP-1 protein is in a posttranslational soluble form.

6. The method of claim 5 , wherein the protein is glycosylated.

7. The method of claim 5 , wherein the protein is phosphorylated.

8. The method of claim 1 , wherein said at least one further biomarker is procalcitonin.

9. The method of claim 1 , wherein the determining step is performed simultaneously.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2011
From: B.R.A.H.M.S AKTIENGESELLSCHAFT
To: B.R.A.H.M.S GMBH
Reel/Frame 025697/0943 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2005
From: BERGMANN, ANDREAS; FISCHER-SCHULZ, CHRISTINA; STRUCK, JOACHIM
To: B.R.A.H.M.S AKTIENGESELLSCHAFT
Reel/Frame 016721/0633 →
Priority Claims (1)
EP 02008840 · Apr 19, 2002 · regional
Continuity (1)
Related Publication 20060029990A1 · Feb 9, 2006